J Nephropathol. 2020;9(1): e08.
doi: 10.15171/jnp.2020.08

Scopus ID: 85078280329
  Abstract View: 1654
  PDF Download: 580

Original Article

Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial

Heshmatollah Shahbazian 1 ORCID logo, Ali Ghorbani 1, Fatemeh Hayati 1, Seyed Seifollah Beladi Mousavi 1,2 ORCID logo, Leila Sabetnia 1* ORCID logo, Shahla Ahmadi Halili 1, Shokouh Shayanpour 1 ORCID logo, Isa Rezaee 1

1 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Tehran University of Medical Sciences, Baharloo Hospital, Tehran, Iran
*Corresponding Author: *Corresponding author: Leila Sabetnia, Email:, Email: Leila.Sabetnia@yahoo.com


Introduction: Thymoglobulin is a lymphocyte-depleting polyclonal antibody, administered for induction therapy at the time of kidney transplantation to reduce the risk of acute allograft rejection. The appropriate dosage and duration of therapy is controversial. The higher dosages are associated with infection and malignancy.

Objectives: In this study efficacy and safety of lower dosage (in comparison with previous studies) of thymoglobulin in kidney transplant recipients was evaluated.

Patients and Methods: In this clinical trial, 106 adult kidney transplant recipients, were randomized before transplantation in two groups (case and control). The case group (53 patients) were received induction therapy with thymoglobulin (1.5 mg/kg/d for 3 days) and the control group (53 patients) were received non-induction regiment. Delayed graft function (DGF), glomerular filtration rate (GFR), acute allograft rejection and thymoglobulin complications were evaluated during the first post-transplantation year.

Results: Around 106 kidney transplant recipients were enrolled (71 or 66.98% deceased donor) to the study. No significant statistical differences were found in GFR at the time of discharge from hospital (P=0.399) and at 1 year (P=0.851) and acute allograft rejection (P= 0.304) between two groups. Graft survival (73.5% in case group versus 81.1% in control group, P=0.392) at month 12th was similar among groups. Additionally, no significant differences of acute allograft rejection in recipient from deceased or living donor between two groups were detected. There was a higher incidence of DGF in the control group (26.4%) than the thymoglobulin group (5.8%) and the difference was statistically significant (P= 0.004). Thrombocytopenia (17% versus 49.1%, P<0.001) and leukopenia (11.3% versus 50.9%, P<0.001) were also significantly higher in the case group.

Conclusion: While the incidence of DGF was reduced in thymoglobulin group, the short-term acute allograft rejection rate was not reduced compared to the control group. However, our results require further consideration with larger samples

Implication for health policy/practice/research/medical education:

In a randomized clinical trial on 106 kidney transplant recipients, we found that induction therapy with thymoglobulin did not associate with reduction in acute allograft rejection or improvement of graft survival.

Please cite this paper as: Shahbazian H, Ghorbani A, Hayati F, Beladi Mousavi SS, Sabetnia L, Ahmadi Halili S, et al. Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial. J Nephropathol. 2020;9(1):e08. DOI: 10.15171/jnp.2020.08.

First Name
Last Name
Email Address
Security code

Abstract View: 1655

Your browser does not support the canvas element.

PDF Download: 580

Your browser does not support the canvas element.

Submitted: 07 Aug 2018
Accepted: 27 Apr 2019
ePublished: 10 Jun 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)